{
  "prompt": {
    "prompt": "Original Transcript:\n**Professional Medical Clerking – SBAR Format**  \n\n---  \n\n### **SITUATION:**  \n**Patient Demographics:**  \n- **Name:** Ms. X (DOB: 15/05/1985, 39yo)  \n- **Gestation:** N/A (G4P2, previous SVD x2, LSCS x1)  \n- **Presenting Complaint:** Abnormal uterine bleeding (AUB) – heavy menstrual bleeding (HMB) with intermenstrual bleeding (IMB) for 3/12, worsening over last 2/52.  \n- **Key Clinical Issue:** Persistent AUB with associated fatigue (likely secondary to iron deficiency anemia). No hemodynamic instability at present.  \n\n### **BACKGROUND:**  \n**Relevant PMHx:**  \n- **OBGYN Hx:**  \n  - G4P2 (2x SVD, 1x LSCS for FTP, 1x TOP)  \n  - Previous IUD (Mirena®) removed 6/12 ago due to expulsion  \n  - No known fibroids or endometriosis  \n- **Medical Hx:**  \n  - Hypothyroidism (on levothyroxine 75mcg OD)  \n  - Obesity (BMI 32)  \n  - No known coagulopathy  \n- **Surgical Hx:**  \n  - LSCS (2018)  \n  - Appendicectomy (2005)  \n- **Medications:**  \n  - Levothyroxine 75mcg OD  \n  - NSAIDs PRN for dysmenorrhea (no recent use)  \n- **Allergies:** NKDA  \n- **Social Hx:**  \n  - Non-smoker, occasional ETOH  \n  - Works as a teacher, moderately active  \n\n**Risk Factors for AUB:**  \n- Obesity (↑ endometrial hyperplasia risk)  \n- Hypothyroidism (may exacerbate HMB)  \n- Previous IUD expulsion (possible structural cause)  \n\n### **ASSESSMENT:**  \n**Clinical Findings (0800 hours):**  \n- **Vitals:**  \n  - BP: 128/78 mmHg  \n  - HR: 88 bpm (regular)  \n  - Temp: 36.7°C  \n  - SpO₂: 98% RA  \n  - RR: 14/min  \n- **General Exam:**  \n  - Pale conjunctivae (clinical anemia)  \n  - No signs of hemodynamic compromise  \n- **Abdo Exam:**  \n  - Soft, non-tender, no palpable masses  \n- **PV Exam (consented & chaperoned):**  \n  - No active bleeding at time of exam  \n  - Cervix appears normal, no cervical excitation  \n  - Uterus anteverted, non-tender, normal size  \n  - No adnexal masses  \n\n**Investigations:**  \n- **Bloods (FBC, LFTs, U&Es, CRP, TFTs, coagulation screen):**  \n  - Hb: 98 g/L (↓ from 112 g/L 6/12 ago)  \n  - MCV: 78 fL (microcytic)  \n  - Ferritin: 12 μg/L (↓)  \n  - TSH: 2.1 mIU/L (well-controlled)  \n  - Platelets: 220 x10⁹/L  \n  - INR/APTT: Normal  \n- **Imaging:**  \n  - **TV USS:**  \n    - Endometrial thickness: 12mm (heterogeneous)  \n    - No fibroids/polyps seen  \n    - Normal adnexa  \n  - **Pipelle biopsy (awaiting histology)**  \n\n**Differential Diagnosis (PALM-COEIN):**  \n1. **Polyp/Adenomyosis** (USS inconclusive, biopsy pending)  \n2. **Endometrial hyperplasia** (↑ risk due to obesity)  \n3. **Coagulopathy** (unlikely given normal coagulation)  \n4. **Ovulatory dysfunction** (secondary to hypothyroidism?)  \n5. **Iatrogenic** (none identified)  \n\n### **RECOMMENDATION:**  \n**Immediate Management:**  \n- **Iron supplementation:** Ferrous sulfate 200mg BD + vitamin C (monitor Hb in 4/52)  \n- **Hormonal therapy:**  \n  - Start norethisterone 5mg TDS for 21/7 (to regulate bleeding)  \n  - Consider Mirena® IUD reinsertion if biopsy normal  \n- **Analgesia:** Mefenamic acid 500mg TDS PRN (if dysmenorrhea). For hysteroscopy preparation: advise mefenamic acid 500mg 1 hour pre-procedure (in addition to PRN use for dysmenorrhea)  \n\n**Monitoring & Follow-Up:**  \n- **Repeat Hb in 4/52** (target >110 g/L)  \n- **Await endometrial biopsy results** (exclude hyperplasia/malignancy)  \n- **GYN OPD follow-up in 6/52 with hysteroscopy clinic appointment scheduled (to be canceled only if biopsy confirms benign diagnosis AND bleeding resolves completely with medical management)**  \n\n**Further Investigations if Needed:**  \n- If endometrial biopsy results are inconclusive, arrange outpatient hysteroscopy with vaginoscopic approach using miniaturized hysteroscope (≤3.5mm) and saline distension  \n- If USS/biopsy inconclusive, arrange outpatient hysteroscopy with: (1) vaginoscopic approach, (2) mini-hysteroscope (≤3.5mm), (3) warmed saline distension at lowest effective pressure, (4) pre-procedure NSAIDs  \n\n**Patient Counseling:**  \n- Prior to any hysteroscopy, provide written information including: procedure details, pain management options (NSAIDs recommended), potential need to stop if distressing, and contact details for questions  \n\n**Contingencies:**  \n- If hemodynamically unstable → admit for IV iron/transfusion  \n- If biopsy shows hyperplasia → consider progestogens/hysterectomy (if completed family)  \n\n---  \n**Documented by:** [Your Name] (FY2)  \n**Reviewed by:** [Consultant Name] (Obstetrics & Gynaecology)  \n**Time/Date:** 0800 hours, 05/06/2024  \n\n*(This is a fictional case for educational purposes only.)*\n\nApply these changes:\nACCEPT: Replace \"Consider Mirena® IUD reinsertion if biopsy normal\" with \"Recommend LNG-IUS (Mirena®) as first-line treatment if biopsy shows hyperplasia without atypia\" (Reason: According to the guideline: 'The first-line medical treatment for hyperplasia without atypia is the levonorgestrel-releasing intrauterine system (LNG-IUS) due to its higher regression rate and fewer adverse effects compared to oral progestogens.' This patient has risk factors for hyperplasia (obesity) and the current plan only considers IUD if biopsy is normal, missing the opportunity for first-line treatment if hyperplasia is confirmed. This change aligns with evidence-based management.)\nACCEPT: Replace \"Gap: no specified duration for progestogen treatment if hyperplasia confirmed\" with \"If hyperplasia confirmed, specify minimum 6 months progestogen treatment with follow-up biopsies every 6 months until two consecutive negative results\" (Reason: The guideline states: 'Treatment should last for a minimum of 6 months to induce regression. Endometrial surveillance should be done every 6 months, with at least two consecutive negative biopsies before discharge.' This is particularly relevant given the patient's elevated BMI (32) which increases hyperplasia risk. The current plan lacks this critical follow-up protocol.)\nACCEPT: Replace \"GYN OPD follow-up in 6/52 with hysteroscopy clinic appointment scheduled\" with \"GYN OPD follow-up in 6/52 with hysteroscopy clinic appointment scheduled (contingent on biopsy results) AND weight loss counseling referral\" (Reason: The guideline emphasizes: 'Weight loss should be advised for obese women with endometrial hyperplasia.' Given this patient's BMI of 32 and endometrial thickness of 12mm, weight management is a key modifiable risk factor that should be addressed concurrently with medical management.)\nACCEPT: Replace \"Missing: specific contingency plan for atypical hyperplasia findings\" with \"Add contingency: If biopsy shows atypical hyperplasia → urgent referral to gynecologic oncology for hysterectomy consideration (given patient is G4P2 with completed family)\" (Reason: The guideline clearly states: 'Total hysterectomy is advised for women with atypical hyperplasia to reduce the risk of underlying malignancy or cancer progression.' This patient has completed her family (G4P2) making her an appropriate candidate for definitive surgical management if atypia is found. The current plan lacks this critical pathway.)\nACCEPT: Replace \"Start norethisterone 5mg TDS for 21/7 (to regulate bleeding)\" with \"If using oral progestins temporarily while awaiting biopsy results, document plan to switch to LNG-IUS if hyperplasia confirmed\" (Reason: While the guideline states 'LNG-IUS is first-line for hyperplasia', it acknowledges oral progestins may be used temporarily. However, the current documentation doesn't explicitly state the transitional plan to evidence-based therapy if hyperplasia is confirmed. This clarification ensures guideline-concordant care progression.)\n\nReturn the updated transcript with these changes applied.",
    "system_prompt": "You are a medical AI assistant that applies user decisions to clinical transcripts based on guideline suggestions.\n\nYou will receive:\n1. An original transcript\n2. A list of suggestions with user decisions (accept, reject, or modify)\n3. For modifications, the user's custom text\n\nYour task is to apply only the ACCEPTED and MODIFIED suggestions to create an updated transcript. For each change:\n- ACCEPTED suggestions: Apply the suggested text exactly as provided\n- MODIFIED suggestions: Apply the user's modified text instead of the original suggestion\n- REJECTED suggestions: Leave the original text unchanged\n\nReturn the updated transcript as clean, properly formatted medical text. Maintain the original structure and formatting as much as possible while incorporating the accepted changes.\n\nImportant guidelines:\n- Only apply changes that the user has accepted or modified\n- Preserve the medical accuracy and professional tone\n- Maintain logical flow and readability\n- Do not add any explanatory text or comments\n- Return only the updated transcript",
    "session_id": "advice_1751403369225_oq6ojq0t1",
    "original_transcript_length": 4531,
    "changes_applied": 5,
    "decisions_summary": {
      "accepted": 5,
      "modified": 0,
      "rejected": 0
    }
  },
  "response": "**Professional Medical Clerking – SBAR Format**  \n\n---  \n\n### **SITUATION:**  \n**Patient Demographics:**  \n- **Name:** Ms. X (DOB: 15/05/1985, 39yo)  \n- **Gestation:** N/A (G4P2, previous SVD x2, LSCS x1)  \n- **Presenting Complaint:** Abnormal uterine bleeding (AUB) – heavy menstrual bleeding (HMB) with intermenstrual bleeding (IMB) for 3/12, worsening over last 2/52.  \n- **Key Clinical Issue:** Persistent AUB with associated fatigue (likely secondary to iron deficiency anemia). No hemodynamic instability at present.  \n\n### **BACKGROUND:**  \n**Relevant PMHx:**  \n- **OBGYN Hx:**  \n  - G4P2 (2x SVD, 1x LSCS for FTP, 1x TOP)  \n  - Previous IUD (Mirena®) removed 6/12 ago due to expulsion  \n  - No known fibroids or endometriosis  \n- **Medical Hx:**  \n  - Hypothyroidism (on levothyroxine 75mcg OD)  \n  - Obesity (BMI 32)  \n  - No known coagulopathy  \n- **Surgical Hx:**  \n  - LSCS (2018)  \n  - Appendicectomy (2005)  \n- **Medications:**  \n  - Levothyroxine 75mcg OD  \n  - NSAIDs PRN for dysmenorrhea (no recent use)  \n- **Allergies:** NKDA  \n- **Social Hx:**  \n  - Non-smoker, occasional ETOH  \n  - Works as a teacher, moderately active  \n\n**Risk Factors for AUB:**  \n- Obesity (↑ endometrial hyperplasia risk)  \n- Hypothyroidism (may exacerbate HMB)  \n- Previous IUD expulsion (possible structural cause)  \n\n### **ASSESSMENT:**  \n**Clinical Findings (0800 hours):**  \n- **Vitals:**  \n  - BP: 128/78 mmHg  \n  - HR: 88 bpm (regular)  \n  - Temp: 36.7°C  \n  - SpO₂: 98% RA  \n  - RR: 14/min  \n- **General Exam:**  \n  - Pale conjunctivae (clinical anemia)  \n  - No signs of hemodynamic compromise  \n- **Abdo Exam:**  \n  - Soft, non-tender, no palpable masses  \n- **PV Exam (consented & chaperoned):**  \n  - No active bleeding at time of exam  \n  - Cervix appears normal, no cervical excitation  \n  - Uterus anteverted, non-tender, normal size  \n  - No adnexal masses  \n\n**Investigations:**  \n- **Bloods (FBC, LFTs, U&Es, CRP, TFTs, coagulation screen):**  \n  - Hb: 98 g/L (↓ from 112 g/L 6/12 ago)  \n  - MCV: 78 fL (microcytic)  \n  - Ferritin: 12 μg/L (↓)  \n  - TSH: 2.1 mIU/L (well-controlled)  \n  - Platelets: 220 x10⁹/L  \n  - INR/APTT: Normal  \n- **Imaging:**  \n  - **TV USS:**  \n    - Endometrial thickness: 12mm (heterogeneous)  \n    - No fibroids/polyps seen  \n    - Normal adnexa  \n  - **Pipelle biopsy (awaiting histology)**  \n\n**Differential Diagnosis (PALM-COEIN):**  \n1. **Polyp/Adenomyosis** (USS inconclusive, biopsy pending)  \n2. **Endometrial hyperplasia** (↑ risk due to obesity)  \n3. **Coagulopathy** (unlikely given normal coagulation)  \n4. **Ovulatory dysfunction** (secondary to hypothyroidism?)  \n5. **Iatrogenic** (none identified)  \n\n### **RECOMMENDATION:**  \n**Immediate Management:**  \n- **Iron supplementation:** Ferrous sulfate 200mg BD + vitamin C (monitor Hb in 4/52)  \n- **Hormonal therapy:**  \n  - If using oral progestins temporarily while awaiting biopsy results, document plan to switch to LNG-IUS if hyperplasia confirmed  \n  - Recommend LNG-IUS (Mirena®) as first-line treatment if biopsy shows hyperplasia without atypia  \n- **Analgesia:** Mefenamic acid 500mg TDS PRN (if dysmenorrhea). For hysteroscopy preparation: advise mefenamic acid 500mg 1 hour pre-procedure (in addition to PRN use for dysmenorrhea)  \n\n**Monitoring & Follow-Up:**  \n- **Repeat Hb in 4/52** (target >110 g/L)  \n- **Await endometrial biopsy results** (exclude hyperplasia/malignancy)  \n- **GYN OPD follow-up in 6/52 with hysteroscopy clinic appointment scheduled (contingent on biopsy results) AND weight loss counseling referral**  \n\n**Further Investigations if Needed:**  \n- If endometrial biopsy results are inconclusive, arrange outpatient hysteroscopy with vaginoscopic approach using miniaturized hysteroscope (≤3.5mm) and saline distension  \n- If USS/biopsy inconclusive, arrange outpatient hysteroscopy with: (1) vaginoscopic approach, (2) mini-hysteroscope (≤3.5mm), (3) warmed saline distension at lowest effective pressure, (4) pre-procedure NSAIDs  \n\n**Patient Counseling:**  \n- Prior to any hysteroscopy, provide written information including: procedure details, pain management options (NSAIDs recommended), potential need to stop if distressing, and contact details for questions  \n\n**Contingencies:**  \n- If hemodynamically unstable → admit for IV iron/transfusion  \n- If biopsy shows hyperplasia → specify minimum 6 months progestogen treatment with follow-up biopsies every 6 months until two consecutive negative results  \n- If biopsy shows atypical hyperplasia → urgent referral to gynecologic oncology for hysterectomy consideration (given patient is G4P2 with completed family)  \n\n---  \n**Documented by:** [Your Name] (FY2)  \n**Reviewed by:** [Consultant Name] (Obstetrics & Gynaecology)  \n**Time/Date:** 0800 hours, 05/06/2024  \n\n*(This is a fictional case for educational purposes only.)*",
  "endpoint": "applyDynamicAdvice",
  "timestamp": "2025-07-01T20-57-10",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\n**Professional Medical Clerking – SBAR Format**  \\n\\n---  \\n\\n### **SITUATION:**  \\n**Patient Demographics:**  \\n- **Name:** Ms. X (DOB: 15/05/1985, 39yo)  \\n- **Gestation:** N/A (G4P2, previous SVD x2, LSCS x1)  \\n- **Presenting Complaint:** Abnormal uterine bleeding (AUB) – heavy menstrual bleeding (HMB) with intermenstrual bleeding (IMB) for 3/12, worsening over last 2/52.  \\n- **Key Clinical Issue:** Persistent AUB with associated fatigue (likely secondary to iron deficiency anemia). No hemodynamic instability at present.  \\n\\n### **BACKGROUND:**  \\n**Relevant PMHx:**  \\n- **OBGYN Hx:**  \\n  - G4P2 (2x SVD, 1x LSCS for FTP, 1x TOP)  \\n  - Previous IUD (Mirena®) removed 6/12 ago due to expulsion  \\n  - No known fibroids or endometriosis  \\n- **Medical Hx:**  \\n  - Hypothyroidism (on levothyroxine 75mcg OD)  \\n  - Obesity (BMI 32)  \\n  - No known coagulopathy  \\n- **Surgical Hx:**  \\n  - LSCS (2018)  \\n  - Appendicectomy (2005)  \\n- **Medications:**  \\n  - Levothyroxine 75mcg OD  \\n  - NSAIDs PRN for dysmenorrhea (no recent use)  \\n- **Allergies:** NKDA  \\n- **Social Hx:**  \\n  - Non-smoker, occasional ETOH  \\n  - Works as a teacher, moderately active  \\n\\n**Risk Factors for AUB:**  \\n- Obesity (↑ endometrial hyperplasia risk)  \\n- Hypothyroidism (may exacerbate HMB)  \\n- Previous IUD expulsion (possible structural cause)  \\n\\n### **ASSESSMENT:**  \\n**Clinical Findings (0800 hours):**  \\n- **Vitals:**  \\n  - BP: 128/78 mmHg  \\n  - HR: 88 bpm (regular)  \\n  - Temp: 36.7°C  \\n  - SpO₂: 98% RA  \\n  - RR: 14/min  \\n- **General Exam:**  \\n  - Pale conjunctivae (clinical anemia)  \\n  - No signs of hemodynamic compromise  \\n- **Abdo Exam:**  \\n  - Soft, non-tender, no palpable masses  \\n- **PV Exam (consented & chaperoned):**  \\n  - No active bleeding at time of exam  \\n  - Cervix appears normal, no cervical excitation  \\n  - Uterus anteverted, non-tender, normal size  \\n  - No adnexal masses  \\n\\n**Investigations:**  \\n- **Bloods (FBC, LFTs, U&Es, CRP, TFTs, coagulation screen):**  \\n  - Hb: 98 g/L (↓ from 112 g/L 6/12 ago)  \\n  - MCV: 78 fL (microcytic)  \\n  - Ferritin: 12 μg/L (↓)  \\n  - TSH: 2.1 mIU/L (well-controlled)  \\n  - Platelets: 220 x10⁹/L  \\n  - INR/APTT: Normal  \\n- **Imaging:**  \\n  - **TV USS:**  \\n    - Endometrial thickness: 12mm (heterogeneous)  \\n    - No fibroids/polyps seen  \\n    - Normal adnexa  \\n  - **Pipelle biopsy (awaiting histology)**  \\n\\n**Differential Diagnosis (PALM-COEIN):**  \\n1. **Polyp/Adenomyosis** (USS inconclusive, biopsy pending)  \\n2. **Endometrial hyperplasia** (↑ risk due to obesity)  \\n3. **Coagulopathy** (unlikely given normal coagulation)  \\n4. **Ovulatory dysfunction** (secondary to hypothyroidism?)  \\n5. **Iatrogenic** (none identified)  \\n\\n### **RECOMMENDATION:**  \\n**Immediate Management:**  \\n- **Iron supplementation:** Ferrous sulfate 200mg BD + vitamin C (monitor Hb in 4/52)  \\n- **Hormonal therapy:**  \\n  - Start norethisterone 5mg TDS for 21/7 (to regulate bleeding)  \\n  - Consider Mirena® IUD reinsertion if biopsy normal  \\n- **Analgesia:** Mefenamic acid 500mg TDS PRN (if dysmenorrhea). For hysteroscopy preparation: advise mefenamic acid 500mg 1 hour pre-procedure (in addition to PRN use for dysmenorrhea)  \\n\\n**Monitoring & Follow-Up:**  \\n- **Repeat Hb in 4/52** (target >110 g/L)  \\n- **Await endometrial biopsy results** (exclude hyperplasia/malignancy)  \\n- **GYN OPD follow-up in 6/52 with hysteroscopy clinic appointment scheduled (to be canceled only if biopsy confirms benign diagnosis AND bleeding resolves completely with medical management)**  \\n\\n**Further Investigations if Needed:**  \\n- If endometrial biopsy results are inconclusive, arrange outpatient hysteroscopy with vaginoscopic approach using miniaturized hysteroscope (≤3.5mm) and saline distension  \\n- If USS/biopsy inconclusive, arrange outpatient hysteroscopy with: (1) vaginoscopic approach, (2) mini-hysteroscope (≤3.5mm), (3) warmed saline distension at lowest effective pressure, (4) pre-procedure NSAIDs  \\n\\n**Patient Counseling:**  \\n- Prior to any hysteroscopy, provide written information including: procedure details, pain management options (NSAIDs recommended), potential need to stop if distressing, and contact details for questions  \\n\\n**Contingencies:**  \\n- If hemodynamically unstable → admit for IV iron/transfusion  \\n- If biopsy shows hyperplasia → consider progestogens/hysterectomy (if completed family)  \\n\\n---  \\n**Documented by:** [Your Name] (FY2)  \\n**Reviewed by:** [Consultant Name] (Obstetrics & Gynaecology)  \\n**Time/Date:** 0800 hours, 05/06/2024  \\n\\n*(This is a fictional case for educational purposes only.)*\\n\\nApply these changes:\\nACCEPT: Replace \\\"Consider Mirena® IUD reinsertion if biopsy normal\\\" with \\\"Recommend LNG-IUS (Mirena®) as first-line treatment if biopsy shows hyperplasia without atypia\\\" (Reason: According to the guideline: 'The first-line medical treatment for hyperplasia without atypia is the levonorgestrel-releasing intrauterine system (LNG-IUS) due to its higher regression rate and fewer adverse effects compared to oral progestogens.' This patient has risk factors for hyperplasia (obesity) and the current plan only considers IUD if biopsy is normal, missing the opportunity for first-line treatment if hyperplasia is confirmed. This change aligns with evidence-based management.)\\nACCEPT: Replace \\\"Gap: no specified duration for progestogen treatment if hyperplasia confirmed\\\" with \\\"If hyperplasia confirmed, specify minimum 6 months progestogen treatment with follow-up biopsies every 6 months until two consecutive negative results\\\" (Reason: The guideline states: 'Treatment should last for a minimum of 6 months to induce regression. Endometrial surveillance should be done every 6 months, with at least two consecutive negative biopsies before discharge.' This is particularly relevant given the patient's elevated BMI (32) which increases hyperplasia risk. The current plan lacks this critical follow-up protocol.)\\nACCEPT: Replace \\\"GYN OPD follow-up in 6/52 with hysteroscopy clinic appointment scheduled\\\" with \\\"GYN OPD follow-up in 6/52 with hysteroscopy clinic appointment scheduled (contingent on biopsy results) AND weight loss counseling referral\\\" (Reason: The guideline emphasizes: 'Weight loss should be advised for obese women with endometrial hyperplasia.' Given this patient's BMI of 32 and endometrial thickness of 12mm, weight management is a key modifiable risk factor that should be addressed concurrently with medical management.)\\nACCEPT: Replace \\\"Missing: specific contingency plan for atypical hyperplasia findings\\\" with \\\"Add contingency: If biopsy shows atypical hyperplasia → urgent referral to gynecologic oncology for hysterectomy consideration (given patient is G4P2 with completed family)\\\" (Reason: The guideline clearly states: 'Total hysterectomy is advised for women with atypical hyperplasia to reduce the risk of underlying malignancy or cancer progression.' This patient has completed her family (G4P2) making her an appropriate candidate for definitive surgical management if atypia is found. The current plan lacks this critical pathway.)\\nACCEPT: Replace \\\"Start norethisterone 5mg TDS for 21/7 (to regulate bleeding)\\\" with \\\"If using oral progestins temporarily while awaiting biopsy results, document plan to switch to LNG-IUS if hyperplasia confirmed\\\" (Reason: While the guideline states 'LNG-IUS is first-line for hyperplasia', it acknowledges oral progestins may be used temporarily. However, the current documentation doesn't explicitly state the transitional plan to evidence-based therapy if hyperplasia is confirmed. This clarification ensures guideline-concordant care progression.)\\n\\nReturn the updated transcript with these changes applied.\",\n  \"system_prompt\": \"You are a medical AI assistant that applies user decisions to clinical transcripts based on guideline suggestions.\\n\\nYou will receive:\\n1. An original transcript\\n2. A list of suggestions with user decisions (accept, reject, or modify)\\n3. For modifications, the user's custom text\\n\\nYour task is to apply only the ACCEPTED and MODIFIED suggestions to create an updated transcript. For each change:\\n- ACCEPTED suggestions: Apply the suggested text exactly as provided\\n- MODIFIED suggestions: Apply the user's modified text instead of the original suggestion\\n- REJECTED suggestions: Leave the original text unchanged\\n\\nReturn the updated transcript as clean, properly formatted medical text. Maintain the original structure and formatting as much as possible while incorporating the accepted changes.\\n\\nImportant guidelines:\\n- Only apply changes that the user has accepted or modified\\n- Preserve the medical accuracy and professional tone\\n- Maintain logical flow and readability\\n- Do not add any explanatory text or comments\\n- Return only the updated transcript\",\n  \"session_id\": \"advice_1751403369225_oq6ojq0t1\",\n  \"original_transcript_length\": 4531,\n  \"changes_applied\": 5,\n  \"decisions_summary\": {\n    \"accepted\": 5,\n    \"modified\": 0,\n    \"rejected\": 0\n  }\n}\n\nA: **Professional Medical Clerking – SBAR Format**  \n\n---  \n\n### **SITUATION:**  \n**Patient Demographics:**  \n- **Name:** Ms. X (DOB: 15/05/1985, 39yo)  \n- **Gestation:** N/A (G4P2, previous SVD x2, LSCS x1)  \n- **Presenting Complaint:** Abnormal uterine bleeding (AUB) – heavy menstrual bleeding (HMB) with intermenstrual bleeding (IMB) for 3/12, worsening over last 2/52.  \n- **Key Clinical Issue:** Persistent AUB with associated fatigue (likely secondary to iron deficiency anemia). No hemodynamic instability at present.  \n\n### **BACKGROUND:**  \n**Relevant PMHx:**  \n- **OBGYN Hx:**  \n  - G4P2 (2x SVD, 1x LSCS for FTP, 1x TOP)  \n  - Previous IUD (Mirena®) removed 6/12 ago due to expulsion  \n  - No known fibroids or endometriosis  \n- **Medical Hx:**  \n  - Hypothyroidism (on levothyroxine 75mcg OD)  \n  - Obesity (BMI 32)  \n  - No known coagulopathy  \n- **Surgical Hx:**  \n  - LSCS (2018)  \n  - Appendicectomy (2005)  \n- **Medications:**  \n  - Levothyroxine 75mcg OD  \n  - NSAIDs PRN for dysmenorrhea (no recent use)  \n- **Allergies:** NKDA  \n- **Social Hx:**  \n  - Non-smoker, occasional ETOH  \n  - Works as a teacher, moderately active  \n\n**Risk Factors for AUB:**  \n- Obesity (↑ endometrial hyperplasia risk)  \n- Hypothyroidism (may exacerbate HMB)  \n- Previous IUD expulsion (possible structural cause)  \n\n### **ASSESSMENT:**  \n**Clinical Findings (0800 hours):**  \n- **Vitals:**  \n  - BP: 128/78 mmHg  \n  - HR: 88 bpm (regular)  \n  - Temp: 36.7°C  \n  - SpO₂: 98% RA  \n  - RR: 14/min  \n- **General Exam:**  \n  - Pale conjunctivae (clinical anemia)  \n  - No signs of hemodynamic compromise  \n- **Abdo Exam:**  \n  - Soft, non-tender, no palpable masses  \n- **PV Exam (consented & chaperoned):**  \n  - No active bleeding at time of exam  \n  - Cervix appears normal, no cervical excitation  \n  - Uterus anteverted, non-tender, normal size  \n  - No adnexal masses  \n\n**Investigations:**  \n- **Bloods (FBC, LFTs, U&Es, CRP, TFTs, coagulation screen):**  \n  - Hb: 98 g/L (↓ from 112 g/L 6/12 ago)  \n  - MCV: 78 fL (microcytic)  \n  - Ferritin: 12 μg/L (↓)  \n  - TSH: 2.1 mIU/L (well-controlled)  \n  - Platelets: 220 x10⁹/L  \n  - INR/APTT: Normal  \n- **Imaging:**  \n  - **TV USS:**  \n    - Endometrial thickness: 12mm (heterogeneous)  \n    - No fibroids/polyps seen  \n    - Normal adnexa  \n  - **Pipelle biopsy (awaiting histology)**  \n\n**Differential Diagnosis (PALM-COEIN):**  \n1. **Polyp/Adenomyosis** (USS inconclusive, biopsy pending)  \n2. **Endometrial hyperplasia** (↑ risk due to obesity)  \n3. **Coagulopathy** (unlikely given normal coagulation)  \n4. **Ovulatory dysfunction** (secondary to hypothyroidism?)  \n5. **Iatrogenic** (none identified)  \n\n### **RECOMMENDATION:**  \n**Immediate Management:**  \n- **Iron supplementation:** Ferrous sulfate 200mg BD + vitamin C (monitor Hb in 4/52)  \n- **Hormonal therapy:**  \n  - If using oral progestins temporarily while awaiting biopsy results, document plan to switch to LNG-IUS if hyperplasia confirmed  \n  - Recommend LNG-IUS (Mirena®) as first-line treatment if biopsy shows hyperplasia without atypia  \n- **Analgesia:** Mefenamic acid 500mg TDS PRN (if dysmenorrhea). For hysteroscopy preparation: advise mefenamic acid 500mg 1 hour pre-procedure (in addition to PRN use for dysmenorrhea)  \n\n**Monitoring & Follow-Up:**  \n- **Repeat Hb in 4/52** (target >110 g/L)  \n- **Await endometrial biopsy results** (exclude hyperplasia/malignancy)  \n- **GYN OPD follow-up in 6/52 with hysteroscopy clinic appointment scheduled (contingent on biopsy results) AND weight loss counseling referral**  \n\n**Further Investigations if Needed:**  \n- If endometrial biopsy results are inconclusive, arrange outpatient hysteroscopy with vaginoscopic approach using miniaturized hysteroscope (≤3.5mm) and saline distension  \n- If USS/biopsy inconclusive, arrange outpatient hysteroscopy with: (1) vaginoscopic approach, (2) mini-hysteroscope (≤3.5mm), (3) warmed saline distension at lowest effective pressure, (4) pre-procedure NSAIDs  \n\n**Patient Counseling:**  \n- Prior to any hysteroscopy, provide written information including: procedure details, pain management options (NSAIDs recommended), potential need to stop if distressing, and contact details for questions  \n\n**Contingencies:**  \n- If hemodynamically unstable → admit for IV iron/transfusion  \n- If biopsy shows hyperplasia → specify minimum 6 months progestogen treatment with follow-up biopsies every 6 months until two consecutive negative results  \n- If biopsy shows atypical hyperplasia → urgent referral to gynecologic oncology for hysterectomy consideration (given patient is G4P2 with completed family)  \n\n---  \n**Documented by:** [Your Name] (FY2)  \n**Reviewed by:** [Consultant Name] (Obstetrics & Gynaecology)  \n**Time/Date:** 0800 hours, 05/06/2024  \n\n*(This is a fictional case for educational purposes only.)*\n\n--- Token Usage Report ---\nPrompt tokens: 2142\nCompletion tokens: 1375\nTotal tokens: 3517\nEstimated cost: $0.001758",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 2142,
    "completion_tokens": 1375,
    "total_tokens": 3517,
    "estimated_cost_usd": 0.0017584999999999999
  }
}